ASTRAZENECA PLC
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of world's leading pharmaceutical companies, with leadership in gastrointestinal, neuroscience, cardiovascular, respiratory, oncology and infection product sales. With the acquisition of Medimmune, AstraZeneca now has a significant position in biologicals and vaccines. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. With approximately 67 000 employees, AstraZeneca's headquarters are in London.
Worldwide, AstraZeneca has 17 principal R&D centres, employing 13 000 people in 8 countries: Canada, China, France, India, Japan, Sweden, the UK and the USA. AstraZeneca
has manufacturing activities in more than 20 countries.
Scientists at AstraZeneca have discovered and developed
many of today's leading prescription medicines. AstraZeneca,
a global leader in the development of cancer therapies, is
committed to continuing the fight against cancer, through
early detection and awareness programmes and through
fundamental medical advances. AstraZeneca scientists are
focused on developing a broad portfolio of anti-cancer
products to extend and improve the quality of patients' lives.
Over the past 30 years, AstraZeneca has developed effective
cancer medicines for patients with breast and prostate cancer.AstraZeneca produces Casodex (bicalutamide), the world's
leading anti-androgen, Zoladex (goserelin acetate), the second
largest-selling LHRH agonist in the world, Nolvadex, the first
anti-oestrogen used in breast cancer, and the pure antioestrogen,
Faslodex. We have also introduced a highly effective
and well-tolerated third generation aromatase inhibitor,
Arimidex, that has shown superior efficacy to the previous gold
standard hormonal treatment for breast cancer, Tamoxifen.
Current R&D focuses on developing treatment options across
the prostate and breast cancer continuum, and specifically on
novel biologically targeted approaches such as EGFR-TK
inhibition, VEGFR-TK inhibition and vascular targeting.
AstraZeneca also has a major interest in diabetes and
obesity, and stress-related disorders. In these conditions,
AstraZeneca is looking for novel therapies that are a
significant improvement on current treatments.
AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK
http://www.astrazeneca.com